Intercept Pharmaceuticals to Host 2013 Full Year Financial Results and Business Update Conference Call on March 17

Intercept Pharmaceuticals to Host 2013 Full Year Financial Results and
Business Update Conference Call on March 17

NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc.
(Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver and intestinal diseases, today announced that it will
report 2013 full year financial results after the NASDAQ Market closes on
Friday, March 14, 2014. Intercept management will conduct a conference call
and audio webcast on Monday, March 17, 2014 at 8:30 a.m. EDT to discuss these
results and provide an update on the company's business.

Date: March 17, 2014
Time: 8:30 AM ET

Listen via Internet: http://ir.interceptpharma.com/

Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=63531&k=48456EB8

Toll-free: (855) 232-3919
International: (315) 625-6894

A replay of the call will be available on Intercept's website approximately
two hours after the completion of the call and will be archived for two weeks.

Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver and intestinal diseases utilizing its expertise in bile acid chemistry.
The company's lead product candidate, obeticholic acid (OCA), is a bile acid
analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is
being developed for a variety of chronic liver diseases including primary
biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal
hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA
has received orphan drug designation in both the United States and Europe for
the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside
of Japan and China, where it has out-licensed the product candidate to
Dainippon Sumitomo Pharma (DSP). For more information about Intercept, please
visit the Company's website at: www.interceptpharma.com.

CONTACT: Intercept Pharmaceuticals, Inc.
         Barbara Duncan or Senthil Sundaram
         646-747-1000
         investors@interceptpharma.com
 
Press spacebar to pause and continue. Press esc to stop.